Immunotherapy: Considerations for Advanced Practitioners in Oncology
Develop your expertise in side effect management, recognition, and timing for immunotherapy-related adverse events for several disease states, including melanoma, non–small cell lung cancer, and urothelial carcinoma. Join the presenters as they show how to put the information into practice through case-based discussions.
This immunotherapy educational activity is sponsored by unrestricted educational grants from AstraZeneca Pharmaceuticals LP and Merck Sharp & Dohme Corp.
Program Chair
Laura J. Zitella, MS, RN, ACNP-BC, AOCN®
Stanford Health Center
Faculty
R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA
Winship Cancer Institute of Emory University
Faculty
Mollie Reed, MSN, RN, ACNP-BC
Tennessee Oncology
Overview of Immunotherapy
Laura J. Zitella, R. Donald Harvey and Mollie Reed
Posted: 12/1/2017
Expires: 11/30/2018
Credits/Contact Hours: 2.25
* This link will take you to the
Educational Measures website.
Case Studies in Renal Cell Carcinoma
R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA
Winship Cancer Institute at Emory University
Case Studies in Urothelial Carcinoma
Laura J. Zitella, MS, RN, ACNP-BC, AOCN®
Standford Health Center
Posted: 12/1/2017
Expires: 11/30/2018
Credits/Contact Hours: 0.5
* This link will take you to the
Educational Measures website.
Case Studies in Melanoma
Mollie Reed, MSN, RN, ACNP-BC
Tennessee Oncology
Case Studies in Non-Small Cell Lung Cancer
R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA
Winship Cancer Institute at Emory University
Posted: 12/1/2017
Expires: 11/30/2018
Credits/Contact Hours: 0.5
* This link will take you to the
Educational Measures website.
Case Studies in Head and Neck Cancer
Mollie Reed, MSN, RN, ACNP-BC
Tennessee Oncology
Case Studies in Hodgkin Lymphoma
Laura J. Zitella, MS, RN, ACNP-BC, AOCN®
Standford Health Center
Posted: 12/1/2017
Expires: 11/30/2018
Credits/Contact Hours: 0.5
* This link will take you to the
Educational Measures website.
These CME/CE/CPE certified activities are jointly provided by
 |
 |
 |
 |
